Selwyn Spangenthal

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 216 citations · Full text

Asthma, Pulmonary Care, Phase 2B +6

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 168 citations · Full text

Asthma, Severe Eosinophilic Asthma, Allergy +10

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

Andrew Menzies‐Gow, Michael E. Wechsler, Christopher E. Brightling et al. · The Lancet Respiratory Medicine · 2023 · 127 citations · Full text

Asthma, Rheumatology, Allergy +9

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

Gary T. Ferguson, J. Mark FitzGerald, Eugene R. Bleecker et al. · The Lancet Respiratory Medicine · 2017 · 121 citations

Asthma, Rheumatology, Allergy Medicine +7

Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD

Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson et al. · CHEST Journal · 2016 · 102 citations

Pulmonary Care, Advanced Lung Disease, Pulmonary Medicine +3